Search Filters

Search Results

Found 55 results

510(k) Data Aggregation

    K Number
    K250093

    Validate with FDA (Live)

    Date Cleared
    2025-09-26

    (255 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Linshom Continuous Predictive Respiratory Monitoring System (CPRMS) is indicated for use by healthcare professionals in healthcare facilities, such as procedural areas and recovery rooms, to monitor breathing in adult, (at least 22 years of age) patients.

    The CPRMS is a non-invasive system that graphically displays temperature changes against time and reports values of respiratory rate and seconds since last breath, along with a trend of tidal volume.

    CPRMS measurements are used as an adjunct to other clinical information sources.

    Device Description

    The Linshom CPRMS (Continuous Predictive Respiratory Monitoring System) is a portable and reliable system for detection of spontaneous respiration. It's non-invasive and is not corrupted by motion artifacts. The system autonomously adapts to the local thermal environment to deliver a usable signal without complicated hardware and firmware processing.

    AI/ML Overview

    N/A

    Ask a Question

    Ask a specific question about this device

    K Number
    K250934

    Validate with FDA (Live)

    Manufacturer
    Date Cleared
    2025-08-05

    (130 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Respiree Cardio-Respiratory Monitor is a respiratory monitor intended for hospitals and hospital-type facilities in non-ICU settings and home settings.

    The Respiree Cardio-Respiratory Monitor is indicated for the non-invasive spot checking of respiration rate (RR) for adult patients.

    Device Description

    The Respiree Cardio-Respiratory Monitor System comprised of the following devices:

    • Respiree Cardio-Respiratory Monitor
    • Respiree Gateway and accessories (Antenna, charging cable)
    • Respiree Dashboard

    The Respiree Cardio-Respiratory Monitor is a wearable respiratory monitor. For measurement of respiration rate (RR), the device is affixed to the chest using a disposable adhesive patch with a hook-and-loop fastener to attach to the monitor. The device uses a vertical-cavity surface-emitting diode to emit optical light directed toward the skin. An integrated photodetector in a nearby position senses the diffused collected light. An adaptive signal processing method is used to enhance the device respiratory rate measurements by splitting the signal processing optimizations across different respiratory rate bands.

    The monitor is powered by a 3.7V rechargeable, lithium-ion battery and is charged using the gateway provided. The Respiree Cardio-Respiratory Monitor transmits respiration rate raw data to the gateway via AES 256 encrypted Bluetooth wireless technology, and the latter uploads the data to the fixed secured cloud server either via Wi-Fi or LTE.

    The Respiree Dashboard is a web application user interface that enable healthcare professional to access recorded respiration rate information for spot patient monitoring. The data from the Respiree Cardio- respiratory Monitor are intended for use by healthcare professionals as an aid to diagnosis and treatment. The device is not intended for use on critical care patients.

    AI/ML Overview

    The provided FDA 510(k) clearance letter and summary for the Respiree Cardio-Respiratory Monitor System (K250934) indicate that clinical studies were not required for this specific submission, as there was "no change in the respiration rate software algorithm cleared in the previous version of the device (K223681)." This implies that the performance data for the respiration rate measurement itself was established in a prior submission (K223681).

    Therefore, I cannot extract specific details about new clinical studies for K250934 that would directly prove the device meets acceptance criteria for respiration rate measurement within this document. The document primarily focuses on demonstrating substantial equivalence based on the updated hardware, expanded use environment (home setting), and data presentation methods, leveraging the previous clearance for the core measurement accuracy.

    However, I can infer information about the acceptance criteria for the respiration rate measurement and the reported device performance based on the comparison table with the predicate devices. The other requested information (sample size, experts, adjudication, MRMC, standalone, ground truth, training set details) is typically found in the clinical study report itself, which is not part of this 510(k) summary for K250934.

    Inference from K250934 Document (based on predicate comparison):

    1. Table of Acceptance Criteria and Reported Device Performance (Inferred from Predicate Comparison)

    MetricAcceptance Criteria (Implied)Reported Device Performance (as stated for both subject and primary predicate)
    Respiration Rate (RR) Performance Accuracy (ARMS)< 3 rpm< 3 rpm
    Respiration Rate (RR) Performance Range5 – 50 rpm5 – 50 rpm

    Explanation of Inferences:

    • The document explicitly states that the subject device "uses the identical technology (i.e., same sensor units and algorithms) for measuring respiratory rate compared to the primary predicate."
    • The "Performance Accuracy (Arms)" and "Performance Range" are listed as identical for the subject device and the primary predicate, implying that these are the established performance characteristics for the core respiration rate measurement, and these values serve as the reported device performance and implicitly, the acceptance criteria derived from the predicate.

    Information NOT available in the provided document for the core respiration rate measurement (as no new clinical study was conducted for K250934 to re-evaluate RR accuracy):

    1. Sample size used for the test set and the data provenance: Not present for a new RR accuracy study. This information would have been part of the K223681 submission.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): Not present for a new RR accuracy study.
    3. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not present for a new RR accuracy study.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable for a spot-checking respiration rate monitor. This device measures a physiological parameter, not for interpreting medical images.
    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: The "Performance Accuracy (Arms) < 3rpm" implies a standalone performance measure of the algorithm against a reference standard. However, the details of how this was established (e.g., specific study design, reference standard) are not in this document.
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not specified in this document for the RR measurement. For respiration rate, this typically involves a highly accurate reference method like capnography, impedance pneumography, or manually adjudicated observation.
    7. The sample size for the training set: Not present.
    8. How the ground truth for the training set was established: Not present.

    Additional Study Information Available in the Document for K250934:

    The document highlights the studies conducted to support the changes in the device (home use, hardware modifications, data presentation), rather than re-validating the core RR measurement where the algorithm remained unchanged:

    • Software verification and validation: Confirmed acceptability for intended use.
    • Biocompatibility testing: According to ISO 10993-5 and -10 for patient-contacting components.
    • Human factors and usability testing: Conducted by intended users to support acceptability of risks associated with clinical use.
    • Electrical, EMC, and Wireless Coexistence requirements: Meeting IEC 60601-1, IEC 60601-1-11, IEC 60601-1-2, and C63.27:2021.

    In summary, the provided document leverages the prior clearance (K223681) for the respiration rate measurement accuracy, focusing the current submission (K250934) on demonstrating substantial equivalence for design changes and the expanded use environment.

    Ask a Question

    Ask a specific question about this device

    K Number
    K243183

    Validate with FDA (Live)

    Date Cleared
    2025-06-27

    (270 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The RTM Vital Signs RTMsense is indicated for use by healthcare professionals in healthcare facilities, such as post-operative care and general wards, to monitor breathing in adult (at least 22 years old) patients.

    RTMsense is a non-invasive system that graphically displays respiratory function against time and reports respiratory rate.

    RTMsense measurements are used as an adjunct to other clinical information sources.

    Device Description

    The RTMsense Respiratory Monitoring System is a single use wearable device consisting of a wearable trachea sound sensor (TSS) and software that continuously measures a patient's respiratory rate by analyzing the sounds of air flow within the proximal trachea during inhalation and exhalation. The acoustic signal is transmitted wirelessly to a Lenovo Tablet, and the respiratory measurement values are displayed on the tablet after analysis of the acoustic data by a proprietary software algorithm.

    The RTMsense software application has three parts: firmware on the TSS, a web-based application on the Lenovo tablet, and a cloud-based proprietary software algorithm. The TSS securely transmits acoustic data wirelessly to the local, Bluetooth low energy enabled Lenovo tablet. The tablet uses a web-based application to securely transmit the acoustic data to the cloud for analysis in RTM's proprietary cloud-based algorithm. The web application retrieves the processed data from the algorithm to display respiratory rate on the tablet.

    The device will be used by healthcare professionals in healthcare facilities such as post-operative care or general wards. The RTMsense respiratory measurements are used as an adjunct to other clinical information sources.

    The TSS is held in place by a flexible wearable carrier adhered to the patient's proximal trachea with commercially available medical grade adhesive. The TSS contains the audio sensor, onboard processing, wireless communications technology, and Lithium-ion coin cell rechargeable battery. A custom charger is provided to charge the battery.

    AI/ML Overview

    The provided FDA 510(k) clearance letter and summary for the RTM Sense (A-0001) device details several aspects of its performance and validation. However, it does not explicitly provide a table of acceptance criteria for specific metrics, instead focusing on overall "passing" of predefined performance criteria. The information regarding ground truth establishment for the training set, number and qualifications of experts, and adjudication methods is also limited.

    Based on the provided text, here's an attempt to reconstruct the information:


    Overview of RTM Sense (A-0001) Performance Study

    The RTM Sense (A-0001) is a non-invasive respiratory monitoring system that continuously measures a patient's respiratory rate by analyzing tracheal sounds. The device, intended for use by healthcare professionals in healthcare facilities, underwent non-clinical and clinical performance testing to demonstrate its safety and effectiveness and establish substantial equivalence to predicate devices.

    1. Acceptance Criteria and Reported Device Performance

    While explicit acceptance criteria are not presented in a table format within the document, the "Clinical Performance Testing" section describes primary endpoints that serve as de facto acceptance criteria. The results indicate that the device met these criteria.

    Metric (Implied Acceptance Criteria)RTMsense Performance (Study #1)RTMsense Performance (Study #2)
    Accuracy (Mean Absolute Error)0.58 b/min ($\le$ 1 BPM)0.38 b/min ($\le$ 1 BPM)
    Mean Accuracy Error (%)2.30% (< 5%)2.94% (< 5%)
    Intraclass Correlation Coefficient0.989 and 0.994 (p<0.0001)Not reported for Study #2, but "No statistically significant difference in RR between RTM and Reference p=0.856" implies high correlation.
    Statistical Difference in RRNot explicitly stated as acceptance, but p<0.0001 and p=0.856 respectively indicate no significant difference from gold standard for both studies.No statistically significant difference (p=0.856)

    Note: The acceptance criteria are inferred from the "Primary endpoints assessed were accuracy ≤ 1 BPM and mean accuracy error < 5%."

    2. Sample Size and Data Provenance for Test Set

    • Total Sample Size: Combined, the studies included 44 subjects and over 150 breath samples.
      • Study #1: 31 subjects and 124 breath samples.
      • Study #2: 13 subjects and 65 breath samples.
    • Data Provenance: The document does not explicitly state the country of origin. It indicates that the studies were prospective comparative studies.

    3. Number of Experts and Qualifications for Ground Truth

    The document does not specify the number of experts or their qualifications used to establish the ground truth for the test set.

    4. Adjudication Method for the Test Set

    The document does not describe any specific adjudication method for the test set. Ground truth was established by "Manually scored End-Tidal CO2 breath counts from the capnometer." This suggests a direct technical measurement rather than expert consensus requiring adjudication.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    No MRMC study was conducted or reported. The study design focused on comparing the device's measurements directly against a gold standard (capnometer), not on how AI assistance improves human reader performance. Therefore, no effect size for human reader improvement with AI assistance is provided.

    6. Standalone (Algorithm Only) Performance Study

    Yes, a standalone performance study was conducted. The "Clinical Performance Testing" directly evaluates the RTMsense device's (which includes its proprietary software algorithm) accuracy against a gold standard respiratory measurement (Hamilton C-1 Ventilator with integrated Capnostat 5 capnometer). The reported results (accuracy, bias, % error) are based on the algorithm's performance in calculating respiratory rate from acoustic signals.

    7. Type of Ground Truth Used

    The ground truth used for the clinical performance testing was technical measurement/outcomes data. Specifically, "Manually scored End-Tidal CO2 breath counts from the capnometer" from a Hamilton C-1 Ventilator with integrated Capnostat 5 capnometer were used as the gold standard reference.

    8. Sample Size for the Training Set

    The document does not specify the sample size used for the training set. It only describes the clinical validation (test set) data.

    9. How the Ground Truth for the Training Set was Established

    The document does not describe how the ground truth for the training set was established. It only refers to "RTM's proprietary cloud-based algorithm" that processes acoustic data and "Software Verification / Validation Testing" which states "Integration and algorithm testing was conducted to verify the software meets its requirements and accurately reports respiration rate." This implies internal validation of the algorithm, but details about the training data and its ground truth establishment are absent.

    Ask a Question

    Ask a specific question about this device

    K Number
    K243966

    Validate with FDA (Live)

    Manufacturer
    Date Cleared
    2025-04-09

    (107 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    FH Vitals SDK-RR is a software-only respiratory rate measurement tool intended to be integrated into third-party software applications on compatible mobile devices, laptops, or computers. It is intended for spot checking of Respiration Rate (RR) in an automatic contactless manner by analyzing chest wall movement from video input when the subject is still and properly positioned in front of the camera in a well-lit environment.

    FH Vitals SDK-RR is intended for use under the supervision of a healthcare professional, either in clinical or home environments, and is not intended for continuous monitoring, apnea detection, or as the sole method for evaluating physical health. It is intended to serve as a supplemental tool to assist in the overall assessment of the patient. The software is indicated for use on individuals aged 18 years and older who do not require critical care or continuous vital sign monitoring.

    Device Description

    The FaceHeart Vitals Software Development Kit (FH Vitals SDK-RR) is a software product designed for integration into various software applications, such as those on mobile devices, laptops, or computers. This SDK is strictly a software-only product and is compatible with the following operating systems: Windows 10, Android 14, and iOS 17. It has been tested and is currently only compatible with the following cameras:

    • Logitech C930 webcam
    • Samsung S24+, S24+ smartphone front-facing cameras
    • iPhone 15 Pro, and iPhone 15 Pro Max front-facing cameras

    The SDK is non-contact and designed to measure the respiratory rate in breaths per minute based on facial video streams. When the SDK receives a video stream, it first identifies and tracks the face within the video, ensuring consistent positioning of the face. Based on the tracked facial region, the system identifies the chest as the region of interest (RoI) and locates reliable key points. The system then focuses on the movement of the chest within the RoI to further determine the number of respiratory cycles. By analyzing the frequency of chest elevation and depression, the SDK calculates the respiratory rate in breaths per minute.

    FH Vitals SDK-RR is designed for non-invasive respiratory rate measurement with a validated measurement range of 5-36 bpm. The SDK is not intended for apnea monitoring or detecting the cessation of breathing. FH Vitals SDK-RR is a prescription-use software device that must be used under the clinical supervision or instruction of a licensed healthcare professional (HCP).

    AI/ML Overview

    Here's a detailed breakdown of the acceptance criteria and the study proving the device meets them, based on the provided FDA 510(k) Clearance Letter and 510(k) Summary.

    Acceptance Criteria and Device Performance

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance CriteriaReported Device Performance
    Respiratory Rate Measurement Range5-36 bpm (Predicate: 7-30 bpm; Subject device: 5-36 bpm, validated through clinical testing, aligning with intended use population)
    Performance (Error Level)±2 bpm (Predicate: ±3 bpm; Subject device: Root Mean Square Error (RMSE) for all tested devices was 1.2 bpm (95% CI), demonstrating deviations consistently within ±2 bpm when compared to the gold standard. p-values for RMSE > 2 bpm were below 0.001, indicating statistical significance.)
    Measurement Window60 seconds (Same as predicate)
    Performance Across Respiratory Rate LevelsRMSE ≤2 bpm across all RR ranges (5-8 bpm: RMSE 1.7-1.8 bpm; 9-11 bpm: RMSE 1.0-1.1 bpm; 12-19 bpm: RMSE 1.0-1.3 bpm; 20-29 bpm: RMSE 0.9-1.0 bpm; 30+ bpm: RMSE 1.1-1.2 bpm for all devices. All p-values < 0.001 for RMSE > 2 bpm)
    Statistical Significancep-values for RMSE > 2 bpm were below 0.001, confirming the results were statistically significant.
    Consistency Across DevicesCoefficient of determination (R²) values exceeded 0.98 across all devices, indicating close alignment with the clinical reference device.
    Performance Across DemographicsNo significant differences in accuracy were found based on sex, age, or BMI, confirming consistent performance across demographic groups.
    Performance Across Disease SubgroupsNo major performance issues were noted in cardiovascular, neurological, or pulmonary patients, with minor underestimation in some conditions (e.g., Alzheimer's) still within acceptable limits.
    Clothing Impact on AccuracyNegligible correlation between clothing texture and accuracy, confirming robustness across different clothing types.
    Performance Under Limiting Conditions (for conditions where motion is not intended use)Motion: Up-and-down or back-and-forth motion increased errors; left-and-right motion had the least impact. (Device is not intended for motion conditions). Behavior: Coughing caused significant errors; shallow breathing had minimal effect. User Pose: No difference in accuracy between sitting or lying positions. Illumination: Stable performance across various lighting conditions. Measurement Distance: Accuracy reliable within 1.5 meters but decreased beyond.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: 420 participants
    • Data Provenance:
      • Country of Origin: Taiwan (377 subjects) and United States (43 subjects)
      • Retrospective or Prospective: Not explicitly stated as retrospective or prospective, but the description of "evaluation in a clinical study involving 420 participants" generally implies a prospective collection for the purpose of the study.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    The document does not provide information regarding the number of experts used or their qualifications for establishing the ground truth. It states that the ground truth was established by a "gold standard etCO2 device (manually counted/annotated respiratory rate from analysis of waveform output from the Philips MX100 with Microstream CO2 Extension)." This suggests that human expert annotation may have been involved in the manual counting/annotation, but the specifics are not detailed.

    4. Adjudication Method for the Test Set

    The document does not specify an adjudication method (such as 2+1, 3+1, none) for the test set. The ground truth was derived from a direct comparison to a gold standard medical device.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

    No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The study's focus was on the standalone performance of the FH Vitals SDK-RR against a gold standard, not on the improvement of human readers with AI assistance.

    6. If a Standalone (i.e., Algorithm Only Without Human-in-the-Loop Performance) Was Done

    Yes, a standalone study was done. The entire clinical performance summary describes the FH Vitals SDK-RR (algorithm only) processing video input to measure respiratory rates and comparing these measurements directly against a gold standard device, without human intervention in the measurement process itself.

    7. The Type of Ground Truth Used

    The ground truth used was a gold standard etCO2 device, specifically the "manually counted/annotated respiratory rate from analysis of waveform output from the Philips MX100 with Microstream CO2 Extension." This is a form of physiological measurement data, potentially with human expert review/annotation of that waveform.

    8. The Sample Size for the Training Set

    The document does not provide any information about the sample size used for the training set. The descriptions are exclusively for the clinical performance study (test set).

    9. How the Ground Truth for the Training Set Was Established

    The document does not provide any information on how the ground truth for the training set was established, as the training set details are not included.

    Ask a Question

    Ask a specific question about this device

    K Number
    K242001

    Validate with FDA (Live)

    Date Cleared
    2025-04-04

    (269 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    VitalSigns Camera Medical Library is a software library that can be integrated into a customer application for use during virtual consults or health screening. It is intended for spot checking of Respiration Rate (RR) in an automatic contactless manner as a data point in the overall assessment of the patient. It is used under the supervision of a health care professional, either in the home or in a clinical environment when the subject is still and positioned properly in front of the camera (Samsung Galaxy A20e), which is placed on a stable surface in an adequately lit environment.
    It is intended to be used on patients aged 22 years and older that classify as ASA I (American Society of Anesthesiologists), which is defined as a normal healthy patient, non-smoking and no or minimal alcohol use.
    It is not intended for continuous patient monitoring system or as the sole method of checking the physical health of the patient, nor as an apnea monitor, but as a part of a framework which mandates periodic checks by a health care professional to ensure appropriate clinical diagnosis and treatment can be reached.

    Device Description

    The Philips VitalSigns Camera Medical Library (hereafter known as Philips VSC-MEDlib) is a software library that shall be used in conjunction with a camera which can be part of another platform or as part of a medical device. The Philips VSC-MEDlib incorporates an algorithm which allow for automatic, contactless measuring of Respiration Rate (RR). Philips VSC-MEDlib utilizes the video stream of an unobstructed view of the subject's torso captured from a camera to calculate the RR from torso motion. The video stream can be captured during a video consult or health screening which should always be conducted in the presence of a physician or other Health Care Professional (HCP). The patient must be properly positioned in front of the camera, sitting still and in an adequately lit environment. From a video stream that typically lasts 60 seconds or less, a spot measurement is taken.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study proving the device meets those criteria, based on the provided FDA 510(k) clearance letter:

    Acceptance Criteria and Device Performance

    1. Table of Acceptance Criteria and Reported Device Performance

    CriterionAcceptance Criteria (from Predicate Device/Indication)Reported Device Performance (Philips VitalSigns Camera Medical Library)
    Respiration Rate (RR) Measurement Range8-25 bpm (Predicate Device: Thora-3Di, Model T-01)7-30 bpm (Substantially Equivalent)
    Accuracy (Error/Tolerance)±2 bpm (Predicate Device: Thora-3Di, Model T-01)RMSE was 0.80 [95% CI = 0.582 – 1.017], which meets the primary endpoint of ≤ 3 BPM. (Meets Criteria)
    Measurement Window60 seconds (Predicate Device: Thora-3Di, Model T-01)60 seconds (Same)
    Successful Measurement RateNot explicitly stated as an acceptance criterion for the predicate, but implied by performance.VSC-MEDlib provided a RR output for 83 subjects (93.3% of 92 enrolled).

    Note: While the predicate device had an accuracy of ±2 bpm, the Philips VSC-MEDlib's stated primary endpoint (acceptance criterion) for RMSE was ≤ 3 BPM, which it met. This suggests a slightly less stringent accuracy requirement for the new device, but the FDA still deemed it substantially equivalent based on the overall package of evidence.

    2. Sample Size and Data Provenance

    • Test Set Sample Size: 92 subjects were enrolled in the prospective clinical investigation. VSC-MEDlib provided a RR output for 83 subjects (93.3%).
    • Data Provenance: Single center, prospective clinical investigation conducted in the Netherlands. The study explicitly states the subject population was representative of the intended U.S. population and evaluated performance under suboptimal conditions.

    3. Number of Experts and Qualifications for Ground Truth

    • The document states that the gold standard reference device was manually annotated capnography. It does not specify the number of experts or their qualifications for this manual annotation.

    4. Adjudication Method for the Test Set

    • The document does not specify an adjudication method for establishing the ground truth. It simply states "manually annotated capnography" was used as the gold standard.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • No, a multi-reader multi-case (MRMC) comparative effectiveness study was not reported. The study focused on the standalone performance of the device against a gold standard, not on how human readers' performance might improve with AI assistance.

    6. Standalone Performance

    • Yes, a standalone (algorithm only, without human-in-the-loop performance) study was performed. The clinical investigation directly evaluated the Philips VSC-MEDlib's accuracy in measuring RR against a gold standard reference.

    7. Type of Ground Truth Used

    • The ground truth used was manually annotated capnography. This is considered a gold standard for respiration rate measurement.

    8. Sample Size for the Training Set

    • The document does not provide the sample size used for the training set. It only details the clinical investigation used for performance evaluation (test set).

    9. How the Ground Truth for the Training Set Was Established

    • The document does not provide information on how the ground truth was established for the training set. This is a common omission in 510(k) summaries, which tend to focus on the validation/test set performance.
    Ask a Question

    Ask a specific question about this device

    K Number
    K233953

    Validate with FDA (Live)

    Date Cleared
    2025-03-28

    (469 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Makani Science™ Respiration Monitoring System is indicated for continuous, non-invasive, and real-time monitoring of a patient's breathing. It graphically displays respiration versus time and reports the respiratory rate value.

    The Makani Science™ Respiration Monitoring System is intended to be used by healthcare professionals in healthcare facilities and dental offices on adult patients aged 22 or older. It is not intended to be used as an apnea monitor.

    Device Description

    The Makani Science™ Respiration Monitoring System (Makani Science RMS) is a respiration rate (RR) monitoring system that consists of a pair of identical, battery-powered, wireless, Makani Science Ahe™ Respiration Sensors (Ahe Sensors - piezo-resistive strain sensors) and the Makani Science Ahe™ App (Ahe App), which is deployed and runs on an Apple® iPad®. The two (2) small and lightweight Ahe Sensors are paired to the Ahe App using Bluetooth Low Energy (BLE) 5.0 technology. The Makani Science RMS is intended to be used by trained healthcare providers (HCPs) in the management of their patients. The Ahe Sensors are single-patient use sensors and can be used up to 24 hours of continuous use. The sensors are applied to the patient's intact skin using an adhesive tape built into the sensors and are made to be retained on the skin in nonambulatory use situations, such as supine on a procedure room table or semi-recumbent in a dental chair. One sensor is applied to the patient's thoracic region and the other sensor is applied to the abdomen region. Correct placement of these sensors is important to the effectiveness of the device, and specific guidance is provided to the user in the labeling on where to place the sensors. The Ahe App is a software application, which guides the user through system setup and monitoring using display screens. During use, the iPad is forced into guided access, or "kiosk" mode, which prevents the user from using any other applications during the monitoring session. Once setup is complete and monitoring initiated, the Ahe App displays a graphical rendition and numerical value of the patient's RR. Low and high RR alarm thresholds provide a visual and audible notification if the patient's RR violates the user-determined alarm thresholds. Monitoring continues until the user terminates the monitoring session, at which time the Ahe App can save a report of the monitoring session to an external memory card, if desired by the user. No patient health information (PHI) is retained by the Ahe App after completion of the monitoring session. The Makani Science RMS does not interact with any third-party medical or non-medical devices other than a memory card that is used to store a report of the patient's monitoring session.

    AI/ML Overview

    The Makani Science™ Respiration Monitoring System is designed for continuous, non-invasive, and real-time monitoring of a patient's breathing, graphically displaying respiration versus time and reporting the respiratory rate value. It is intended for use by healthcare professionals in healthcare facilities and dental offices on adult patients aged 22 or older.

    Acceptance Criteria and Reported Device Performance

    Although specific numerical acceptance criteria are not explicitly listed in the provided text, the document states that the device was evaluated against performance requirements, applicable standards, and guidance documents. The key performance metric mentioned is Respiratory Rate (RR) Accuracy.

    Acceptance Criteria (Inferred)Reported Device Performance
    RR Accuracy± 3 BPM

    This reported accuracy is directly compared to the predicate device's accuracy (PMD Solutions / RespiraSense, K220111), which also has an RR Accuracy of ± 3 BPM, indicating that the Makani Science™ RMS meets the established performance benchmark for respiration rate accuracy.

    Study Proving Device Meets Acceptance Criteria

    A clinical performance study was conducted to validate the respiration rate accuracy of the Makani Science™ Respiration Monitoring System.

    1. Sample Size and Data Provenance:

      • Test Set Sample Size: 29 human subjects.
      • Data Provenance: The document does not explicitly state the country of origin, but it is clear the data is from human subjects from the "intended use population," implying a clinical setting. The study appears to be prospective, as it involved actively testing subjects with the device.
    2. Experts for Ground Truth Establishment:

      • The document does not detail the number or qualifications of experts used to establish the ground truth beyond stating "manually counted end-tidal CO2." It is implied that healthcare professionals or trained personnel performed the manual counting.
    3. Adjudication Method:

      • No adjudication method is described. The ground truth was established by "manually counted end-tidal CO2 using an FDA-cleared capnogram," suggesting a direct, objective measurement rather than subjective interpretation requiring adjudication.
    4. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

      • No MRMC comparative effectiveness study was mentioned or performed. The study focused on the device's accuracy against a "gold standard" rather than comparing human reader performance with and without AI assistance.
    5. Standalone Performance:

      • Yes, standalone (algorithm only) performance was assessed. The accuracy of the Makani Science™ RMS was validated against a gold standard method, specifically "manually counted end-tidal CO2 using an FDA-cleared capnogram." This evaluates the device's ability to accurately measure respiratory rate independently.
    6. Type of Ground Truth Used:

      • "Gold standard, manually counted end-tidal CO2 using an FDA-cleared capnogram." This represents a direct, objective physiological measurement.
    7. Training Set Sample Size:

      • The document does not specify the sample size for the training set. The clinical study mentioned is for performance validation, not for training the algorithm.
    8. Ground Truth Establishment for Training Set:

      • The document does not explicitly describe how the ground truth for the training set was established. However, given the nature of the device (respiration monitoring), it can be inferred that training data would likely involve various respiration patterns with corresponding accurate respiratory rate measurements, potentially derived from similar gold standard methods as used for the test set.

    Additional Performance Testing Details:

    The clinical testing also included:

    • RR validation in all four available postures (supine, right side, left side, and reclined).
    • Sub-group analysis to demonstrate maintained RR accuracy regardless of patient demographics (sex, BMI (healthy, overweight, and obese), Fitzpatrick skin type).
    • Accuracy maintained in the presence of comorbidities.
    • Accuracy maintained in the presence of artifacts (e.g., coughing).
    • Accuracy maintained following positional change (e.g., supine → reclined position).
    • Successful demonstration that RR accuracy was maintained over 24 hours of continuous use in bench testing.
    Ask a Question

    Ask a specific question about this device

    K Number
    K242798

    Validate with FDA (Live)

    Device Name
    Airmod
    Date Cleared
    2025-02-28

    (165 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Airmod, when used in conjunction with Accursound Electronic Stethoscope AS-101, is a software as medical device intended to be used for the continuous, non-invasive monitoring of respiratory rate (RR) in adult patients who are subjected to procedural sedation and/or anesthesia.

    Airmod is intended for use by healthcare professionals in hospitals and healthcare facilities who are legally credentialed to perform procedural sedation and/or anesthesia.

    Airmod is intended for Android-based devices only.

    Device Description

    Airmod 114 is an Android-based software application designed to aid healthcare professionals by monitoring a sedated and/or anesthetized patient's breathing in real time. The device has an AIbased algorithm that can detect inhalation acoustics and provides respiratory rates based on the analysis of the acoustic signals of breathing sounds collected by AccurSound Electronic Stethoscope AS-101. Airmodid for the continuous monitoring of respiratory rate (RR) in adults who are subjected to procedural sedation. Airmod™ is designed for use in hospitals and healthcare facilities performing procedural sedation/anesthesia. The device is not intended for patients who are not anesthetized/sedated.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study details for the Airmod device, based on the provided FDA 510(k) summary:

    Acceptance Criteria and Device Performance

    Acceptance CriteriaReported Device Performance (Airmod™)
    Root Mean Square Error (RMSE) < 3 Breaths Per Minute (BPM) when compared to manual-scored capnography (mancRR)RMSE = 2.689 BPM (95% CI: 2.529, 2.695)

    Study Details

    1. Sample Size Used for the Test Set and Data Provenance:
    * Sample Size: 270 participants
    * Data Provenance: The study included both "outside of US (OUS) and US populations." This indicates a combination of retrospective and prospective data, though the document does not explicitly state the temporal nature of the data collection for each region.

    2. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications:
    * The document mentions "manual scored capnography (mancRR)" as the reference for ground truth. However, it does not specify the number of experts used or their qualifications for establishing this ground truth.

    3. Adjudication Method:
    * The document does not specify the adjudication method used for establishing the ground truth from manual-scored capnography.

    4. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
    * No, a multi-reader multi-case (MRMC) comparative effectiveness study was not explicitly described. The clinical testing focused on the non-inferiority of Airmod™'s respiratory rate measurements compared to a capnography system. There is no mention of human readers improving with or without AI assistance.

    5. Standalone Performance Study:
    * Yes, a standalone performance study was done. The clinical testing evaluated the performance of Airmod™ (algorithm only, as a software as medical device) against the Capnostream™35 capnography system. The results of the RMSE directly reflect the algorithm's standalone accuracy.

    6. Type of Ground Truth Used:
    * The ground truth used was manual-scored capnography (mancRR). This provides a direct, physiological measurement of respiratory rate that is then manually interpreted or verified.

    7. Sample Size for the Training Set:
    * The document does not specify the sample size used for the training set of the AI-based algorithm. The 270 participants relate to the clinical testing (test set) for validation.

    8. How the Ground Truth for the Training Set Was Established:
    * The document does not provide details on how the ground truth for the training set was established. It only mentions that the device has an "AI-based algorithm that can detect inhalation acoustics and provides respiratory rates based on the analysis of the acoustic signals."

    Ask a Question

    Ask a specific question about this device

    K Number
    K240271

    Validate with FDA (Live)

    Date Cleared
    2024-09-11

    (224 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Linshom Continuous Predictive Respiratory Monitor System (CPRMS) is indicated for use by healthcare professionals in healthcare facilities, such as procedural areas and recovery rooms, to monitor breathing in adult, (at least 22 years of age) patients.

    The CPRMS is a non-invasive system that graphically displays temperature changes against time and reports values of respiratory rate and seconds since last breath, along with a trend of tidal volume.

    CPRMS measurements are used as an adjunct to other clinical information sources.

    Device Description

    The Linshom CPRMS (Continuous Predictive Respiratory Monitoring System) is portable, reliable and an inexpensive system for precise detection of spontaneous respiration. It is non-invasive and is not corrupted by motion artifacts. The system autonomously adapts to the local thermal environment to deliver a usable signal without complicated hardware and firmware processing.

    AI/ML Overview

    The provided text details the FDA 510(k) clearance for the Linshom Continuous Predictive Respiratory Monitoring System (CPRMS), demonstrating its substantial equivalence to a predicate device. However, the document does not contain specific acceptance criteria, reported device performance metrics in a table, or details regarding the study designs (sample sizes, data provenance, expert qualifications, ground truth establishment, or clinical study effect sizes) that directly prove the device meets pre-defined quantitative acceptance criteria.

    The document primarily focuses on:

    • Regulatory Clearance: The FDA's determination of substantial equivalence for the CPRMS to its predicate device (Linshom Respiratory Monitoring Device - LRMD).
    • Technological Comparison: A table comparing the characteristics of the subject device (CPRMS) and the predicate device (LRMD), highlighting their similarities.
    • Non-Clinical Testing Summary: A general statement about the types of non-clinical tests performed (e.g., Lifetime Test, Movement Test, Respiration Rate Test, Tidal Volume Trend Test) and conformance to various medical device standards. It mentions "Statistical analysis, including correlation methods, showed strong alignment with reference data, indicating that the device functions accurately and reliably within its intended use parameters," but does not provide the specific numerical results of these analyses or the acceptance thresholds.

    Therefore, based solely on the provided text, I cannot complete many of the requested sections.

    Here's a breakdown of what can be inferred from the text and what cannot:

    1. A table of acceptance criteria and the reported device performance

    The document mentions specific accuracy for respiration rate and tidal volume trend for both the subject and predicate devices:

    MetricAcceptance Criteria (Implied)Reported Device Performance (Subject Device - CPRMS)
    Respiration Rate± 1 BPM± 1 BPM
    Tidal Volume TREND~0.97 (r2 correlation)~0.97 (r2 correlation)

    Note: These are presented as specifications that are "Same" for both devices, implying the CPRMS met these already established performance levels of the predicate device. The text does not explicitly state them as "acceptance criteria" for a new study, but rather as inherent accuracy specifications of the device's mechanism.

    2. Sample sized used for the test set and the data provenance

    • Sample Size for Test Set: Not specified. The document states "The subject device [K240271] underwent testing across the full range of physiological parameters, including respiratory rates from 0-60 breaths per minute (BPM)." This implies a test set was used, but its size or specific characteristics (e.g., number of subjects, number of data points) are not provided.
    • Data Provenance: Not specified. It's unclear if the testing was retrospective or prospective, or the country of origin of the data. The testing mentioned appears to be laboratory/non-clinical.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    • Not specified. The document outlines non-clinical testing focused on device performance against reference data, not human expert interpretation of clinical data for ground truth.

    4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

    • Not applicable/Not specified for this type of non-clinical device performance testing. Adjudication methods are typically used in studies involving human interpretation (e.g., image reading).

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No MRMC or human-in-the-loop study is mentioned. The device provides measurements (respiratory rate, seconds since last breath, tidal volume trend) as an adjunct to other clinical information sources, but the text does not describe a study where human readers/clinicians used the device and their performance was evaluated comparatively.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    • Yes, implicitly. The "Non-Clinical and/or Clinical Tests Summary" describes tests where the device's measurements (respiration rate, tidal volume trend) were compared against "reference data," indicating a standalone evaluation of the algorithm's performance against a known standard.

    7. The type of ground truth used

    • Reference Data: The document states "Statistical analysis, including correlation methods, showed strong alignment with reference data." This implies that the ground truth was derived from established, accurate measurement methods or simulated physiological parameters (e.g., a ventilator for tidal volume, a controlled breathing simulator for respiration rate). It's not explicitly stated as expert consensus, pathology, or outcomes data.

    8. The sample size for the training set

    • Not specified. The document mentions "Proprietary Algorithm" for both subject and predicate devices but provides no details on how these algorithms were developed or trained, nor the size of any training datasets.

    9. How the ground truth for the training set was established

    • Not specified. As no training set details are provided, the method for establishing its ground truth is also absent.
    Ask a Question

    Ask a specific question about this device

    K Number
    K223681

    Validate with FDA (Live)

    Manufacturer
    Date Cleared
    2023-03-08

    (90 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Respiree Cardio-Respiratory Monitor is a respiratory monitor intended for hospital-type facilities in non-ICU settings. The Respiree Cardio-Respiratory Monitor is indicated for the non-invasive spot checking of respiration rate (RR) for adult patients.

    Device Description

    The Respiree Cardio-Respiratory Monitor, Model RS001, is a small respiratory monitor. For measurement of respiration rate (RR), the device is affixed to the chest using a disposable adhesive patch with a hook-and-loop fastener to attach to the monitor. The device uses a vertical-cavity surface-emitting diode to emit optical radiation directed toward the skin. An integrated photodetector in a nearby position senses the diffused collected light. An adaptive signal processing method is used to enhance the device respiratory rate measurements by splitting the signal processing optimizations across different respiratory rate bands.

    The monitor is powered by a 3.7V rechargeable, lithium-ion battery and a USB charging cable is provided. The Respiree Cardio-Respiratory Monitor also includes optional Bluetooth wireless technology for the wireless transfer of patient data to mobile devices.

    AI/ML Overview

    Here's a summary of the acceptance criteria and the study that proves the device meets them, based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Performance MetricAcceptance Criteria (Predicate)Reported Device Performance (Respiree Cardio-Respiratory Monitor)
    Performance range5 - 60 rpm5 - 50 rpm
    Accuracy (ARMS)<2 rpm<3 rpm

    2. Sample Size for Test Set and Data Provenance

    • Sample Size: 46 subjects
    • Data Provenance: The document does not explicitly state the country of origin.
    • Retrospective/Prospective: The study was a clinical validation, which typically implies a prospective design where the device is used to collect new data.

    3. Number of Experts Used to Establish Ground Truth and Qualifications

    • Number of Experts: The document states the reference EtCO2 waveform was "manually scored by counting the respiratory peaks per minute." It does not specify the number of experts.
    • Qualifications of Experts: The qualifications of the individuals who performed the manual scoring are not specified in the provided text.

    4. Adjudication Method for the Test Set

    • The document implies that the ground truth was established by manual scoring of the EtCO2 waveform. It does not describe an adjudication method (such as 2+1 or 3+1 consensus) for this manual scoring.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • No, an MRMC comparative effectiveness study was not done. The study described compared the device's performance against a reference standard (EtCO2 waveform) and did not involve human readers using or not using AI.

    6. Standalone (Algorithm Only) Performance

    • Yes, a standalone study was done. The clinical validation was conducted to assess the performance of the Respiree Cardio-Respiratory Monitor device itself in measuring respiratory rate, comparing its output directly to a reference standard.

    7. Type of Ground Truth Used

    • The ground truth used was the EtCO2 waveform manually scored by counting the respiratory peaks per minute. This can be categorized as a type of expert-derived physiological measurement.

    8. Sample Size for the Training Set

    • The document does not specify the sample size for the training set. It only describes the clinical validation study (test set).

    9. How the Ground Truth for the Training Set Was Established

    • As the training set size is not specified, the method for establishing its ground truth is also not provided in the given text.
    Ask a Question

    Ask a specific question about this device

    K Number
    K221555

    Validate with FDA (Live)

    Device Name
    Dozee VS
    Date Cleared
    2022-12-15

    (198 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use
    Device Description
    AI/ML Overview
    Ask a Question

    Ask a specific question about this device

    Page 1 of 6